Last reviewed · How we verify

General Anesthesia: Sevoflurane

Etienne Xavier Keller · FDA-approved active Small molecule Quality 2/100

Sevoflurane, marketed by Etienne Xavier Keller, is a general anesthetic with a well-established presence in the healthcare sector. A key strength is the protection of its core composition patent, which is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the potential increase in competition following the patent expiry, which could erode market share and revenue.

At a glance

Generic nameGeneral Anesthesia: Sevoflurane
SponsorEtienne Xavier Keller
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: